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In spite of all that has been achieved, renal transplantation still pro-
vides a flawed and unpredictable service. In the average American center in 
the decade of the 70's, less than half of the recipients of first cadaver kid-
neys were able to boast of graft function by the end of the first postoperative 
year. One reason may be neglect of what we have been calling the forgotten pre-
treatment principle. It is that subject which we will discuss today, with 
particular emphasis on thoracic duct drainage (TDD). 
EARLY CLUES 
In 25 of our first kidney recipients, Wilson and Kirkpatrick (31) used 
preoperative skin testing and typhoid vaccination to assess cellular and hlli~oral 
immune reactivity. Immunosuppressive therapy for those patients was with aza-
thioprine to which prednisone was added only if rejection developed. After 
transplantation, the patients previously classified as non-responders had a 
mean rejection time of 14.8 days, compared to 4.3 days in the responders. These 
findings were not influenced by donor relationship. ~D:ilson and Kirkpatrick 
concluded that, "These observations support the concept that impaired immunolo-
gic responsiveness in uremia is an important factor in successful human kidney 
transplantation. Furthermore, the difference in rejection times between the 
responsive and unresponsive groups suggests that the reactive group might bene-
fit from additional immunosuppressive therapy prior to ..• ". 
Almost a decade later, the prognostic implication of the reactor versus 
non-reactor state of kidney recipients was re-emphasized by the antibody studies 
of Opelz, Mickey and Terasaki (IS). Hore recently, Jones et al. (8) I Thomas et 
al. (27) and Opelz and Terasaki (16) came to the same conclusion from the re-
sults of in vitro phytohemagglutin, concanavalin A and mixed lymphocyte culture 
U·ILC) tests of which all are expressions of T-lymphocyte reactivity. The l-1LC 
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studies (16) were particularly illuminating. The MLC index using third party 
lymphocytes was almost as predictive of the outcome after cadaveric kidney 
transplantation as when the stimulator cells were provided by the actual donor. 
Although well known, the foregoing information has had surprisingly little 
influence on treatment practices. In the early days of our program almost all 
human kidney recipients were given azathioprine for 8 to 10 days before trans-
plantation. The practice was based upon analogous canine experiments in which 
average homograft survival was thereby doubled over that obtained when the drug 
was started on the day of operation (19). Gradual abandonment of the policy of 
preoperative treatment of our patients with azathioprine and often steroids may 
have been a systematic error inasmuch as other immunosuppressive adjuncts" to 
condition the recipients were not being substituted. As cadaveric transplanta-
tion became more common, practical reasons made pretreatment difficult. The 
waiting period for a cadaver kidney was unpredictable, during which time extra 
infectious risks were introduced by giving azathioprine with or without predni-
sone. Furthermore, there were no accepted guidelines about the appropriate 
duration of such pretreatment. Worldwide, transplantation drifted into the 
practice of starting therapy on the day of grafting. 
THORACIC DUCT DRAINAGE AND THE PRETREATHENT PRINCIPLE 
The immunosuppressive procedure of thoracic duct drainage (TDD) has pro-
vided an unusually analyzable example of the pretreatment principle and of the 
loss of much of the value of this procedure if its timing is wrong. Thoracic 
duct drainage was given a trial in several centers 5 to 15 years ago (1-6, 11-
13, 17, 18, 28, 29) but was never accepted as a major therapeutic tool. This 
was because the scientific framework for its use in humans had not been worked 
out. 
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Contemporaneous TOO 
Eighteen months ago we began a systematic trial with TOO in renal trans-
plantation, starting the lymphoid depletion on the day of grafting along with 
azathioprine, prednisone and sometimes ALG (20, 23). The protocol was similar 
to that usually used by Franksson (5). The results were somewhat better than 
in historical controls without TOO, but vigorous rejection was often encountered 
during the first month (Table 1). The most striking clinical obser"vation was 
that if the TOO was continued, a second graft could often be performed after 
failure of the first (23). It \'las obvious that TOO was being inappropriately 
used for the primary transplant~ Oata in these patients plus prec~se immunolo-
gic studies by Machleder and Paulus (10) in non-transplantation patients estab-
lished that a pronounced immunodepressive influence of TDO was not established 
until about three weeks and that this effect deepened for another week or so. 
Kidneys in our early TOD series were being rejected during this uncovered three 
or four weeks and, in addition, "antibody storms" in the postoperative period 
were often seen (23) with a heavy representation of the so-called warm anti-T 
and anti-B cytotoxic antibodies of the IgG class (26). 
Pretreatment with Thoracic Ouct Orainage (TOD) 
Realizing the flaw in therapeutic strategy (23), a new series was begun 
using TOO in advance of cadaveric renal transplantation (24), adding azathio-
prine and prednisone on the day of operation. This time, the presence of pre-
existing recipient antibodies was taken into consideration. These antibodies 
recently were characterized on the basis of their reactivity against homologous 
T- and B-lymphocytes at warm (IgG class) and cold (lgM) temperatures (26). It 
has been accepted that warm anti-T antibodies cause hyperacute rejection (26), 
but the significance of the other antibody varieties has remained controversial. 
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Whatever their meaning, the cytotoxic antibodies co~ld be construed as an index 
of the patients' immune reactivity, both by their presence before and by their 
development after transplantation. In the new treatnent scheme, patients with 
no (or only cold) antibodies were scheduled for three weeks' preparation with 
TDD. Those possessing warm antibodies were sched.lled for 35 days. If anti-T 
antibodies persisted and reacted against the potential donors, it was shown 
earlier (23) that a low titer was necessary before proceeding in the fact of a 
positive crossmatch. After 35 days, acceptance was recofr~ended of cadaver donors 
whose positive crossmatches were due to other kinds of antibodies. 
The recipients in this new series represented a modern-day-cross-section 
of risk factors. Many of the patients were old with known coronary artery dis-
ease, three were diabetics, and three were undergoing retransplantation. 
Because the donor selection was random except for red cell group compatibility, 
the HLA and DR matches were all poor (24). The results from the studies per-
mitted precise conclusions about TOO pretreatment. 
Pretreatment of Three Weeks. Thirteen consecutive cadaver recipients of 
whom only one had pre-existing warm anti-B antibodies had preoperative TOO for 
17 to 28 days. The therapeutic approach is illustrated in Figure 1. During 
the pretreatment period, the numbers of collected lymphocytes always fell mark-
edly. After transplantation, the TDD was maintained for at least three more 
weeks. 
During follow-ups of two to six months, five of these patients (38%) had 
rejection, which in four instances was reversible (Table 1). The fifth patient 
was treated with prompt retransplantation. These patients retained a potent 
capacity for cytotoxic antibody production. Two weeks after transplantation 
11 of the 13 had developed warm anti-B antibodies against a panel of 30 
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lymphocyte donors, and in seven cases the antibodies rea::::ted against more than 
half of the panel (Table 2). All five of the rejections were in these latter 
seven antibody-producing recipients. One patient died o~e month after trans-
plantation from acute pancreatitis. 
Pretreatment for Four Weeks or Longer. Fourteen co~secutive cadaveric re-
cipients, of whom four had pre-existing warm antibodies, had the longer pre-
treatment of 26 to 58 days. After two to six months only one (7%) patient 
had a rejection (Table 2) and that one was so minor as to be equivocal. At the 
same time, the capacity to generate all categories of cytotoxic antibodies was 
remarkably reduced. Even though four of the 14 recipients already had warm 
antibodies predating TOO, these tended to diminish during pretreatment and only 
one of the 14 possessed broad reacting \'1arm antibodies b.-a \'1eeks post-
transplantation (Table 2). 
Two patients died, one from a virus infection' after seven weeks, and the 
other at two months from a massive lidocaine overdosage given inadvertently by 
her family physician. 
Long-Term Implications 
In these patients, it remains to be seen if a delayed immunologic rebound 
will,cause major kidney losses after discontinuance of thoracic duct drainage. 
However, Walker (30), Johnson (7), and Niblack (14) and t~eir associates have 
not seen a catch-Up deterioration of grafts in patients followed two to five 
years after pre- and postoperative TDO. Late stability a=ter earlier TDD was 
also reported recnetly by Kaplan (9). It seems likely that the poorly under-
stood change in host-graft relationship that has made clinical transplantation 
practical will be expedited rather than hindered by properly timed thoracic 
duct drainage. If so, improvements in early graft survival should be translated 
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into better long-term results. 
BROADER H1PLICATIONS 
If the pretreatment principle delineated by the foregoing experience is 
valid, it will influence other developments and practices in transplantation. 
Other Therapeutic Regimens 
It would be surprising if host conditioning equivalent to that of chronic 
TDD could not be achieved with other means over a period of several. weeks. An 
obvious possibility is mechanical removal of lymphocytes from the peripheral 
blood (lymphaphoresis), a procedure for which commercial instrmnentation is al-
ready available. We have treated two livec recipients and one kidney recipient 
in this way. The procedures of total lymphoid irradiation (25) and thymectomy 
are variations on the same theme. So would be pretransplantation conditioning 
with powerful antilymphocyte sera and globulins, an approach that has been made 
impractical in patients by immune reactions to the heterologous protein (22). 
It is clear that a sufficiently long conditioning period will be required. 
Today for the first time in years, there is the real prospect of better 
drugs for core immunosuppression, of which cyclosporin is the most promising as 
CaIne will tell us today. The potential value of pretreating with cyclosporin 
(or other drugs) or alternatively of combining drugs with preoperative lymphoid 
depletion is obvious. With any such conditioning effort, the use of the battery 
of in vitro immunologic tests now available should permit the curves of pre-
operative immunodepression to be quantitated for individual patients. 
We have in fact treated four patients with cyclosporin following thoracic 
duct drainage (TOO) for 24 to 42 days. The convalescence of these patients has 
been remarkably uncomplicated. Within one or two days after transplantation, 
maneuvers were begun to discontinue the TDO. No steroids or azathioprine were 
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given. It will be interesting to see if cyclosporin itself can be substituted 
for TOO in the pretreatment period. 
Patient Selection and Histocompatibility 
In the past, renal recipients (particularly those needing cadaveric organs) 
always have been ruled by the donors, with the final decision about candidacy 
hinging mainly on the conventional negative cytotoxic crossmatch and, in most 
centers, to a lesser extent on-RLA matching. With effective pretreatment by 
TDO, it has been possible to give weight to the recipient~s wishes.· Based upon 
.. 
the antibody state, a rational decision has been possible about the duration of 
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pretreatment and about the prospects for success without any consideration of 
tissue match. Once the TOO is instituted, the patient has been assured of 
transplantation and at a fairly predictable time. The ability to offer trans-
plantation to cadaveric recipients as an elective and pla~~ed undertaking has 
drastically changed our program. The numbers of consanguineous transplants 
have dwindled to less than 10% of the total as the prospective recipients have 
perceived the improved cadaveric situation. The n~~er of cases which can be 
handled by our fixed bed unit has substantially increased (60 in the last seven 
months), in spite of the time investment for pretreatment which is more than 
cancelled by the ability to discharge patients earlier after a homograft has 
been placed. 
Other Organs 
Improvements in immunosuppression should be applicable for other organs 
including the liver and heart. The direct application of these findings in 
liver recipients may pose special problems. Lymph drainage in patients with 
hepatic disease tends to be voluminous, particularly if ascites is present. 
Recently, we were forced to perform a liver transplant after only 18 days of 
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TOO because the amount of lymph obtained per day had reached 25 liters, a 
volume so great that fluid management was becoming difficult. It may be that 
many of the liver recipients can have safer lymphoid depletion by lymphaphoresis 
or by other kinds of preoperative conditioning discussed earlier. Certainly, 
pretreatment will be a major factor in patient care as our liver program reopens. 
SUMMARY 
Pretreatment with TOO markedly influences early graft survival and vir-
tually eliminates early rejection providing the lymphoid depletion is for at 
least four weeks. SUch preoperative recipient conditioning has markedly im-
proved the quality of patient service. It is probable that the pretreatment 
principle can be applied effectively using other immunosuppressive measures 
including drugs. 
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Figure 1: Example of short pretreatment with TOO. Although the patient had a 
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perfect result, it is now knmm that the conditioning period was too 
brief (see text). The marked drop in lymphocytes. removed during t~e 
pre-transplantation period was invariably observed. This finding 
was in contrast to our experience with TOO started on the day of 
transplantation in which the number of lymphocytes removed +emained 
high (20, 23). The postoperative retention of TDD for about three 
weeks is still pur policy. The patient who is now more than seven 
months after transplantation has had no evidence of late rejection. 
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TABLE 1: REJECTION IN FIRST TWO MONTHS OF CADAVER KIDNEYS: 
INFLUENCE OF THORACIC DUCT DRAINAGE* 
% R E J E C T I o N 
Three \<ieeks ~ Four Weeks 
Contemporaneous Pretreatment Pretreatment 
TDD (17)** With TDD (13) With TDD (14) 
Incidence Rejection 41% 38% 7% 
Irreversible Rejection 24% 8% 0% 
Deaths 0 1 2 
* In 50 immediately precedent cadaveric recipients treated with azathioprine, 
prednisone and sometimes ALG, the incidence of early rejection was 48% (20). 
** Data from (20). 
TABLE 2: BROADLY REACTING* WAR.."'l ANTI-B LYHPHOCYTE ANTIBODIES 
TWO WEEKS AFTER TRANSPLANTATION 
TDO Pretreatment for Three Weeks . . 7/13 
TOD Pretreatment ~ Four Heeks . 1/14 
'* B-roadly reacting means- reactivity against half or more of 
a 30-donor lymphocyte panel. 
